Peptide record

Tirzepatide

Mechanism

39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite.24

Function

Approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials.24

Receptor

Glucose-dependent insulinotropic polypeptide receptor (GIPR) and GLP-1 receptor (GLP1R). 24

Sequence

39-amino-acid GIP-based backbone with multiple substitutions and a C20 fatty diacid side chain; exact residue-level sequence is proprietary but characterized as a 39-aa dual incretin analog.24

Length

39 amino acids

Organism or Origin

Synthetic dual GIP/GLP-1 receptor agonist modeled on human incretin hormones.24 80

Gene

Not assigned in the current dataset.

Sources

24Tirzepatide - a dual GIP and GLP-1 (GLP1) receptor agonist, https://gpnotebook.com/pages/diabetes-and-endocrinology/tirzepatide-a-dual-gip-and-glp-1-glp1-receptor-agonist
80GLP-1 Localisation and Proglucagon Gene Expression in ..., https://pmc.ncbi.nlm.nih.gov/articles/PMC6200298/

GLP-1 Receptor Agonists (Semaglutide Focus)